J Urol 2007, 178:2378–2383.PubMedCrossRef 14. Dreicer R, Petrylak D, Agus D, Webb I, Roth B: Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007, 13:1208–1215.PubMedCrossRef 15. Reddy KG: Activity

of bortezomib in advanced non-small-cell lung cancer. Clin Lung Cancer 2004, 6:141–142.PubMed 16. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, et al.: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5025–5033.PubMedCrossRef 17. Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E: Randomized phase II trial of docetaxel plus Selleckchem AG-881 cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 2009, 27:4487–4491.PubMedCrossRef 18. Li T, Ho L, Piperdi B, Elrafei

T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp LY333531 solubility dmso R: Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade((R))) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 2009. 19. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle QNZ checkpoint by survivin. Nature 1998, 396:580–584.PubMedCrossRef 20. Altieri DC: Survivin in apoptosis control 2-hydroxyphytanoyl-CoA lyase and cell cycle regulation in cancer. Prog Cell Cycle Res 2003, 5:447–452.PubMed 21. Li F: Survivin Study: What is the next wave? J Cell Physiol 2003, 197:8–29.PubMedCrossRef 22. Li F, Ling X: Survivin Study: An update of “”What is the next wave?”". J Cell Physiol 2006, 208:476–486.PubMedCrossRef 23. Pennati M, Folini M, Zaffaroni N: Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008, 12:463–476.PubMedCrossRef 24. Altieri DC: The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006, 18:609–615.PubMedCrossRef

25. Wheatley SP, McNeish IA: Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005, 247:35–88.PubMedCrossRef 26. Zhang M, Yang J, Li F: Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res 2006, 25:391–402.PubMed 27. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al.: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21:2613–2622.PubMedCrossRef 28. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277:3247–3257.PubMedCrossRef 29.